BiotechTubeBiotechTube
Home/Annexon/Ted Yednock, Ph.D.
TY

Ted Yednock, Ph.D.

Executive Vice President and Chief Scientific Officer

Annexon

Therapeutic Areas

Autoimmune DiseasesNeurodegenerative DiseasesOphthalmology

Annexon Pipeline

DrugIndicationPhase
ANX005Guillain-Barré Syndrome (GBS)Phase 2/3
ANX007Geographic Atrophy (GA) secondary to AMDPhase 2
ANX009Complement-mediated diseasesPreclinical

Leadership Team at Annexon

DL
Douglas Love, Esq.
President and Chief Executive Officer
JL
Jennifer Lew, CPA
Chief Financial Officer
MD
M. Dominik Wolff, M.D., M.H.S.
Executive Vice President and Chief Medical Officer
JR
John R. Gargiulo
Chief Business Officer
SS
Sakinah Suttiratana, Ph.D., J.D.
General Counsel and Corporate Secretary
MG
Michael G. Atieh
Chairman of the Board of Directors
MA
Muneer A. Satter
Board Member
MJ
M. James Barrett, Ph.D.
Board Member
BS
Beth Seidenberg, M.D.
Board Member
MK
Maha Katabi, Ph.D.
Board Member
View full Annexon profile